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Antimicrobial activityAbstract A new class of functionalized 3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-
pyrazole scaffolds (4a–q) was synthesized by a four step reaction in good yields. Initially, o-alkyl
derivative of salicyaldehyde (1) readily furnished corresponding 2-acetyl benzofuran (2) on treatment
with potassium tert-butoxide (t-BuOK) in the presence ofmolecular sieves. Further, Claisen–Schmidt
condensation reaction with 4-methoxy benzaldehyde and hydrazine hydrate followed by coupling of
benzoyl chlorides afforded target compounds (4a–q). Representative of the synthesized compounds
was characterized by IR, 1H NMR, 13CNMR, mass, elemental analysis and evaluated for antimicro-
bial and antioxidant activities. The results gathered are allowed to conclude that, all newly synthe-
sized analogues exhibit a certain degree of antimicrobial and antioxidant activities. Among the
analogues, compounds (4h) and (4j) showed an excellent antimicrobial activity in the well plate
method. Meanwhile, compounds (4e–f), (4l) and (4p) showed good antioxidant activity, whereas
compound (4g) and (4q) displayed dominant antioxidant efﬁcacy compared to standard butylated
hydroxy anisole (BHA).
ª 2013 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Benzofuran derivatives are an important class of heterocyclic
compounds that are known to possess important biological
properties. The chemistry of benzofurans in a large number of
natural products has attracted a widespread interest due to their
biological activities and their potential applications as pharma-
cological agents. Benzofurans have played an important role in
medicinal chemistry and have drawn considerable attention due
to their profound physiological and chemotherapeutic proper-
S2686 J. Rangaswamy et al.ties (Vinod et al., 2017) Several benzofuran ring systems bearing
various substituents at the C-2 position are widely distributed in
nature, e.g., ailanthoidol (Fig. 1), an neolignan derivative, has
been reported to have antiviral, antioxidant and antifungal
activities (Kao and Chern, 2001).
Furthermore, most of the compounds prepared from 2-ace-
tylbenzofuran have antimicrobial, anticancer, antitumor, anti-
inﬂammatory activity, antitubulin and also used for treatment
of cardiac arrhythmias (Basawaraj et al., 2001; Rida et al.,
2006; Ujjinamatada et al., 2006; Romagnoli et al., 2008). Ben-
zofuran nucleus may be combined with nitrogen heterocycles
in different ways and the compounds including pyrazole
nucleus (Fig. 2) are known to possess analgesic, anti-inﬂamma-
tory, antipyretic, antiarrhythmic, muscle relaxant, psychoana-
leptic, anticonvulsant, hypotensive, monoamine oxidase
inhibitor, antidiabetic and antibacterial activities (Parekh
et al., 2011; Abdel-Wahab et al., 2008, 2009; Kamal et al.,
2006). In recent years, 1,3,5 trisubstituted pyrazole bearing
benzofuran derivatives exhibited a broad-spectrum of antimi-
crobial activities (Zdemir et al., 2007). Some benzofuran deriv-
atives such as 2-acetylbenzofuran and 2-nitrobenzofuran are
well-known biodynamic agents possessing various pharmaco-
logical properties (Kadin, 1972). On the other side pyrazoline
derivatives are the electron rich nitrogen heterocycles which
play an important role in the diverse biological activities.
These heterocyclic compounds widely occur in nature in the
form of alkaloids, vitamins, pigments and as constituents of
plant and animal cell. Considerable attention has been focused
on the pyrazolines and substituted pyrazolines due to their
interesting biological activities (Mohamad and Payal, 2014).
The literature survey approaching to the synthesis of
pyrazole gathered with benzofuran moiety indicates the few ref-
erences available. In the interest of the above suggestion and in
continuation of our research work on the synthesis of novel
classes of biologically active heterocyclic derivatives (Kumar
and Naik, 2010; Kumar et al., 2011; Naik et al., 2011a,b) and
encouraged by the successful results obtained from these works,
we inspired to design and synthesize the functionalized 3-(ben-
zofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole
scaffolds and examined their biological activities.
2. Experimental
2.1. General
All reagents and solvents were purchased from Merck (Darms-
tadt, Germany) chemical AR grade and used as provided.O
OH
OMe
HO
OMe
Figure 1 Structure of ailanthoidol.DPPH, BHA and ABTS tablet were purchased from Sigma
to Aldrich chemical Co. (St. Louis, MO, USA). Thin layer
chromatography (TLC) analysis was performed on alumina
sheets precoated with silica gel 60F-254 and SiO2, 200–400
mesh (Merck) was used for column chromatography. 1H
NMR (AC 400) and 13C NMR (AC 100) spectra were obtained
by Bruker spectrometer in the appropriate (DMSO-d6) solvent
with TMS as internal reference. Melting points were obtained
on a reichert thermopan melting point apparatus, equipped
with a microscope and are uncorrected. Elemental analysis
was performed on a Thermo Finnigan Flash EA 1112 elemen-
tal analyzer. Mass spectra were obtained by Water-Q-TOF ul-
tima spectrometer.
2.2. Chemistry
Very recently, an efﬁcient, 1,8-diaza biaza bicycle[5,4,0]undec-
7-ene (DBU) assisted one pot synthesis of 2-acetyl benzofuran
via intramolecular cyclo condensation of o-alkylation of sali-
cylaldehyde with chloroacetone was reported (Rangaswamy
et al., 2012). In the present investigation, we described a mild
variant potassium tert-butoxide (t-BuOK) assisted one pot
synthesis of 2-acetyl benzofuran (2) in the presence of molecu-
lar sieves Scheme 1. The mechanism involves, o-alkylation of
salicylaldehyde (IV) with chloroacetone (I) in the presence of
t-BuOK (II) as base furnished o-alkylated salicyaldehyde (V)
which subsequently generates enolate anion (VI) undergo
intramolecular cyclocondensation reaction afforded 2-acetyl
benzofuran (VIII) in excellent yield (Scheme 2). In the next
step, aldol condensation reaction of compound (2) with 4-
methoxy benzaldehyde in the presence of LiOHÆH2O accom-
plished benzofuran chalcone i.e., (E)-1-(benzofuran-2-yl)-3-
(4-methoxyphenyl) prop-2-en-1-one (3) (Srikant et al., 2006).
Generally, chalcones are considered to be useful intermediates
in several cyclization reactions to produce different types of
heterocyclic compounds of diverse biological importance,
according to the reactants used and the reaction conditions
(Yadav et al., 2005; Kim et al., 2005). Benzofuran chalcone
(3) further treated with hydrazine hydrate in ethanol furnished
3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyr-
azole (4). Finally, conjugation of benzofuran scaffold (4) with
benzoyl chlorides in the presence of triethylamine as base
afforded functionalized 3-(benzofuran-2-yl)-5-(4-methoxy-
phenyl)-4,5-dihydro-1H-pyrazole scaffolds (4a-q) (Scheme 1).
2.2.1. Synthesis of 2-acetyl benzofuran (2)
A mixture of salicyaldehyde (1) (2 mmol), chloroacetone
(2 mmol) and potassium tert-butoxide (2 mmol) in 10 mL of
dichloromethane (DCM) containing molecular sieves was re-
ﬂuxed at 30 C for 3 h. Progress of the reaction was monitored
by TLC using hexane:ethyl acetate (8:2) mixture as mobile
phase. After the completion of the reaction, the reaction mix-
ture was washed with 10% HCl solution followed by water.
The organics were dried over anhydrous sodium sulfate. The
yellow solid was obtained by desolventizing in a rotary evapo-
rator at room temperature affords 2-acetyl benzofuran (2).
m.p.: 73–75 C, Yield-92%, IR (KBr) mmax (cm1): 3087 (CH
furan), 2900 (CH3), 1675 (C‚O), 1558 (C‚C);
1H NMR
(DMSO-d6 400 MHz) dppm: 7.46–7.73 (m, 5H, Ar-H), 2.25
(s, 3H, CH3).
13C NMR (DMSO-d6 100 MHz) dppm: 186.0,
160.4, 147.8, 127.6, 124.8, 123.3, 120.9, 111.4, 103.9, 25.5;
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Figure 2 General structures of some bi-active entities of benzofuran combined with pyrazole nucleus.
Functionalized 3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole scaffolds: S2687MS (ESI) m/z: 160.05 (M+). Anal. calcd. for C10H8O2: C,
74.99; H, 5.03; O, 19.98%; found: C, 74.95; H, 5.07; O,
19.96%.
2.2.2. Synthesis of (E)-1-(benzofuran-2-yl)-3-(4-
methoxyphenyl) prop-2-en-1-one (3)
Compound (2) (1 mmol) in ethanol (0.5 mL) was treated with
LiOHÆH2O (4 mg 0.1 mmol, 10 mol%) under magnetically stir-
red condition for 10 min at room temperature (25–30 C) fol-
lowed by 4-methoxy benzaldehyde (1 mmol). The mixture was
stirred magnetically until complete consumption of the com-
pound (2) for 35 min. After the completion of the reaction a
dark yellow precipitate was formed and this served as an indi-
cator for monitoring the reaction. Ethanol was removed under
reduced pressure. The residue was diluted with water (5 mL)
neutralized with 2% aqueous HCl and extracted with ethylace-
tate (3 · 5 mL). The combined ethylacetate extracts were
washed with brine solution (5 mL) dried over anhydrous
Na2SO4 and concentrated under vacuum at room temperature
to afford compound (3). Light yellow solid, m.p. : 118–120 C,
Yield-87%, IR (KBr) mmax (cm
1): 1624 (C‚O), 1455
(CH‚CH); 1H NMR (DMSO-d6 400 MHz) dppm: 7.10–7.60
(m, 9H, Ar-H), 6.75 (s, 2H, CH) 3.81 (m, 3H of OCH3);
13C
NMR (DMSO-d6 100 MHz) dppm: 177.8, 160.4, 155.2,
149.1, 147.8, 145.0, 127.8, 127.5, 124.7, 123.3, 122.9, 121.2,
120.9, 116.7, 111.9, 111.4, 56.1; MS (ESI) m/z: 278.09 (M+).
Anal. calcd. for C18H14O3: C, 73.46; H, 4.79; O, 21.75%;
found: C, 73.44; H, 4.78; O, 21.73%.
2.2.3. Synthesis of 3-(benzofuran-2-yl)-5-(4-methoxyphenyl)4,
5-dihydro-1H-pyrazole (4)
To a solution of (E)-1-(benzofuran-2-yl)-3-(4-methoxy-
phenyl)prop-2-en-1-one (3) (1 mmol) in ethanol as solvent,
hydrazine hydrate (2 mmol) was added and the reaction mix-
ture was reﬂuxed for 3 h. After cooling the mixture was poured
into crushed ice, the precipitate was obtained, ﬁltered andwashed with ethanol (2–5 mL) followed by water, dried in
air and residue was collected (4). Light brown solid, m.p.:
195–197 C, Yield-87%, IR (KBr) mmax (cm1): 3311 (N–H)
and 1595 (C‚N); 1H NMR (DMSO-d6 400 MHz) dppm:
7.10 (s, 1H, N–H), 6.65–7.85 (m, 9H, Ar-H), 3.90–3.98 (dd,
2H, CH2, pyrazoline, J= 4.1 Hz, 5.8 Hz), 3.88 (t, 1H, CH
of pyrazoline, J= 7.5 Hz), 3.71 (s, 3H of OCH3);
13C NMR
(DMSO-d6 100 MHz) dppm: 155.6, 155.0, 147.2, 146.7,
137.0, 134.5, 125.1, 124.7, 123.3, 120.9, 119.4, 115.5, 111.5,
110.2, 104.9, 56.1, 49.0, 40.9; MS (ESI) m/z: 292.12 (M+).
Anal. calcd. for C18H16N2O2: C, 70.12; H, 5.23; N, 9.09; O,
15.57%; found: C, 70.10; H, 5.25; N, 9.11; O, 15.55%. The
spectral and analytical data for compounds (2), (3) and (4)
are in agreement with that reported in the literature (Rangasw-
amy et al., 2012; Bakr et al., 2009; Basawaraj et al., 2009).
2.2.4. General procedure for the synthesis of functionalized 3-
(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-
pyrazole scaffolds (4a-q)
3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyra-
zole (1.2 mmol) was suspended in dry THF (5 mL) in an inert
atmosphere (N2). To this suspension, at room temperature trieth-
ylamine (1.5 mmol) and different benzoyl chlorides (RCOCl)
(1 mmol in 3 mL of THF) were added and reaction mixture was
stirred for 3–4 h. The progress of reactionmixturewasmonitored
byTLCusinghexane:ethylacetate (6:4).The reactionmixturewas
then desolventized in a rotary evaporator and the compound was
extracted in ethylacetate. The ethylacetate layer was washed with
water and dried over anhydrous sodium sulfate. The products
were obtained by further desolventation in a rotary evaporator
at 50 C. The respective products were puriﬁed through column
chromatography using hexane:ethylacetate (6:4).
2.2.4.1. (3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1yl) (phenyl) methanone (4a). Light brown
solid, m.p.: 180–183 C. Spectroscopic analysis: IR (KBr) mmax
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Scheme 1 Reaction pathway for the synthesis of functionalized 3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole
scaffolds (4a-q).
S2688 J. Rangaswamy et al.(cm1): 3131–2973 (Ar-CH), 1680 (C‚O), 1624 (C‚N Pyra-
zole), 1365 (C–N); 1H NMR (DMSO-d6 400 MHz) dppm:
7.72–7.42 (m, 14H, Ar-H), 4.70 (t, 1H, CH of pyrazoline,
J= 7.3 Hz), 3.71–3.95 (dd, 2H, CH2 of pyrazoline,
J= 4.2 Hz, 7.8 Hz), 3.81 (s, 3H, OCH3);
13C NMR (DMSO-
d6 100 MHz) dppm: 165.0, 160.6, 155.5, 149.3, 143.5, 134.2,
131.1, 130.4, 129.9, 129.4, 128.5, 128.4, 125.3, 124.7, 123.1,
120.8, 114.8, 110.3, 104.5, 104.3, 58.7; MS (ESI) m/z: 396.15
(M+). Anal. calcd. for C25H20N2O3: C, 76.13; H, 4.60; N,
7.10; O, 12.17%; found: C, 76.10; H, 4.63; N, 7.12; O, 12.15%.
2.2.4.2. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1yl) (nitrophenyl) methanone (4b). Reddish
brown solid, m.p.: 298–301 C. Spectroscopic analysis: IR
(KBr) mmax (cm
1): 3129–2975 (Ar-CH), 1672 (C‚O), 1641
(C‚N Pyrazole), 1515–1560 (N–O), 1368 (C–N); 1H NMR
(DMSO-d6 400 MHz) dppm: 7.68–7.45 (m, 13H, Ar-H), 4.82
(t, 1H, CH of pyrazoline, J= 7.5 Hz), 3.75–3.97 (dd, 2H,
CH2 of pyrazoline, J= 4.8 Hz, 8.3 Hz), 3.65 (s, 3H, OCH3);13C NMR (DMSO-d6 100 MHz) dppm: 165.5, 159.6, 155.5,
150.3, 143.5, 134.2, 131.1, 130.4, 129.7, 129.3, 128.5, 128.4,
125.3, 124.7, 123.1, 120.8, 114.7, 110.3, 104.5, 104.3, 58.7;
MS (ESI) m/z: 441.13 (M+). Anal. calcd. for C25H19N3O5:
C, 68.02; H, 4.34; N, 9.52; O, 18.12%; found: C, 68.05; H,
4.53; N, 9.44; O, 18.25%.
2.2.4.3. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (3,5 dinitrophenyl) methanone (4c).
Brown solid, m.p.: 213–215 C. Spectroscopic analysis: IR
(KBr) mmax (cm
1): 3129–2975 (Ar-CH), 1675 (C‚O), 1658
(C‚N Pyrazole), 1525–1570 (N–O), 1365 (C–N); 1H NMR
(DMSO-d6 400 MHz) dppm: 7.69–7.53 (m, 12H, Ar-H), 4.62
(t, 1H, CH of pyrazoline, J= 5.5 Hz), 3.72–4.01 (dd, 2H,
CH2 of pyrazoline, J= 4.8 Hz, 6.2 Hz), 3.85 (s, 3H, OCH3);
13C NMR (DMSO-d6 100 MHz) dppm: 165.9, 161.6, 154.3,
149.1, 143.2, 134.0, 131.5, 130.5, 130.7, 129.7, 129.5, 129.8,
128.4, 128.6, 125.2, 124.8, 123.1, 120.9, 115.0, 110.3, 104.7,
104.7, 58.8; MS (ESI) m/z: 486.12 (M+). Anal. calcd. for
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Scheme 2 Mechanism toward the synthesis of 2-acetyl benzofuran by using t-BuOK.
Functionalized 3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole scaffolds: S2689C25H18N4O7: C, 61.73; H, 3.73; N, 11.52; O, 23.02%; found:
C, 62.00; H, 3.53; N, 11.43; O, 23.25%.
2.2.4.4. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (4-hydroxyphenyl) methanone (4d).
Brown semisolid. Spectroscopic analysis: IR (KBr) mmax (cm
1): 3465 (OH), 3122–2985 (Ar-CH), 1664 (C‚O), 1655
(C‚N Pyrazole), 1365–1317 (C–N); 1H NMR (DMSO-d6
400 MHz) dppm: 7.60–7.41 (m, 13H, Ar-H), 5.30 (s, 1H,
OH), 4.70 (t, 1H, CH of pyrazoline, J= 5.0 Hz), 3.71–3.96
(dd, 2H, CH2 of pyrazoline, J= 5.8 Hz, 7.8 Hz), 3.79 (s,
3H, OCH3);
13C NMR (DMSO-d6 100 MHz) dppm: 165.3,
160.5, 155.8, 149.5, 143.6, 134.1, 131.9, 130.7, 129.5, 129.3,
129.3, 129.1, 128.3, 128.4, 125.2, 124.8, 123.1, 120.6, 116.8,
116.1, 115.0, 110.5, 104.7, 104.5, 58.6; MS (ESI) m/z:
412.14 (M+). Anal. calcd. for C25H20 N2O4: C, 72.80; H,
4.89; N, 6.79; O, 15.52% found: C, 72.75; H, 4.69; N, 6.82;
O, 15.51%.
2.2.4.5. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (3 hydroxyphenyl) methanone (4e).
Light yellow semisolid. Spectroscopic analysis: IR (KBr) mmax
(cm1): 3545 (OH), 3135–2943 (Ar-CH), 1691 (C‚O),
1619 (C‚N Pyrazole), 1365–1324 (C–N); 1H NMR (DMSO-
d6 400 MHz) dppm: 7.72–7.42 (m, 13H, Ar-H), 5.25 (s, 1H,
OH), 4.65 (t, 1H, CH of pyrazoline, J= 4.9 Hz), 3.69–3.94
(dd, 2H, CH2 of pyrazoline, J= 4.8 Hz, 7.6 Hz), 3.73 (s, 3H,
OCH3);
13C NMR (DMSO-d6 100 MHz) dppm: 166.0, 161.0,
155.8, 149.2, 143.1, 134.1, 131.3, 130.7, 129.5, 129.2, 128.9,
128.4, 125.2, 124.5, 123.2, 120.4, 116.7, 115.3, 114.7, 110.2,
104.4, 104.5, 58.4; MS (ESI) m/z: 412.14 (M+). Anal. calcd.for C25H20N2O4: C, 72.80; H, 4.89; N, 6.79; O, 15.52% found:
C, 72.78; H, 4.91; N, 6.85; O, 15.61%.
2.2.4.6. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (2-hydroxyphenyl) methanone (4f).
Brown solid. m.p.: 195–198 C. Spectroscopic analysis: IR
(KBr) mmax (cm
1): 3465 (OH), 3135–2963 (Ar-CH), 1675
(C‚O), 1643 (C‚N Pyrazole), 1378–1325 (C–N); 1H NMR
(DMSO-d6 400 MHz) dppm: 7.60–7.41 (m, 13H, Ar-H), 5.36
(s, 1H, OH), 4.58 (t, 1H, CH of pyrazoline, J= 7.8 Hz), 3.68–
3.89 (dd, 2H, CH2 of pyrazoline, J= 4.2 Hz, 7.5 Hz), 3.72 (s,
3H, OCH3);
13C NMR (DMSO-d6 100 MHz) dppm: 166.1,
161.3, 155.8, 149.2, 143.1, 134.1, 131.3, 130.7, 129.5, 129.3,
129.3, 129.0, 128.4, 128.3, 125.6, 124.5, 123.2, 120.4, 116.7,
115.3, 114.5, 110.2, 104.5, 104.3, 58.3; MS (ESI) m/z: 412.14
(M+). Anal. calcd. for C25H20N2O4: C, 72.80; H, 4.89; N,
6.79; O, 15.52% found: C, 72.73; H, 4.93; N, 6.83; O, 15.45%.
2.2.4.7. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (3,4,5 trihydroxyphenyl) methanone
(4g). Yellow semisolid. Spectroscopic analysis: IR (KBr) mmax
(cm1): 3265–3592 (OH), 3261–2933 (Ar-CH), 1678 (C‚O),
1637 (C‚N Pyrazole), 1348 (C–N); 1H NMR (DMSO-d6
400 MHz) dppm: 7.80–7.42 (m, 11H, Ar-H), 5.30–7.03 (s,
3H, OH), 4.93 (t, 1H, CH of pyrazoline, J= 8.3 Hz), 3.71–
3.98 (dd, 2H, CH2 of pyrazoline, J= 3.8 Hz, 6.8 Hz), 3.92
(s, 3H, OCH3);
13C NMR (DMSO-d6 100 MHz) dppm:
165.9, 160.8, 155.3, 149.4, 143.95, 134.5, 131.2, 130.5, 130.0,
129.8, 129.5, 129.2, 128.8, 128.1, 125.8, 125.0, 123.6, 120.9,
116.5, 115.8, 114.5, 110.2, 104.7, 59.0, 37.9; MS (ESI) m/z:
444.13 (M+). Anal. calcd. for C25H20N2O6: C, 67.56; H,
S2690 J. Rangaswamy et al.4.54; N, 6.30; O, 21.60% found: C, 67.50; H, 4.33; N, 6.42; O,
21.45%.
2.2.4.8. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl)(4-ﬂuorophenyl) methanone (4h). Dark
yellow solid, m.p.: 237–240 C. Spectroscopic analysis: IR
(KBr) mmax (cm
1): 3128–2984 (Ar-CH), 1682 (C‚O), 1626
(C‚N Pyrazole), 1354 (C–N), 1255 (C–F); 1H NMR
(DMSO-d6 400 MHz) dppm: 7.69–7.44 (m, 13H, Ar-H), 4.73
(t, 1H, CH of pyrazoline, J= 7.3 Hz), 3.75–4.05 (dd, 2H,
CH2 of pyrazoline, J= 4.0 Hz, 6.5 Hz), 3.83 (s, 3H, OCH3);
13C NMR (DMSO-d6 100 MHz) dppm: 165.9, 161.2, 156.4,
149.4, 144.0, 134.75, 131.1, 130.4, 129.7, 129.4, 129.3, 129.2,
128.5, 128.4, 125.3, 124.7, 123.1, 120.8, 116.5, 115.8, 114.8,
110.3, 104.5, 58.7, 38.1; MS (ESI) m/z: 414.14 (M+), Anal.
calcd. for C25H19FN2O3: C, 72.45; H, 4.62; N, 6.76; O,
11.58% found: C, 72.41; H, 4.59; N, 6.75; O, 11.57%.
2.2.4.9. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (4-bromophenyl) methanone (4i). Brown
semisolid. Spectroscopic analysis: IR (KBr) mmax (cm
1): 3135–
2976 (Ar-CH), 1683 (C‚O), 1628 (C‚N Pyrazole), 1357
(C–N), 524–595 (C–Br); 1H NMR (DMSO-d6 400 MHz)
dppm: 7.58–7.43 (m, 13H, Ar-H), 4.90 (t, 1H, CH of pyrazo-
line, J= 8.8 Hz), 3.74–4.01 (dd, 2H, CH2 of pyrazoline,
J= 5.5 Hz, 8.0 Hz), 3.84 (s, 3H, OCH3);
13C NMR (DMSO-
d6 100 MHz) dppm: 165.1, 160.9, 155.2, 149.3, 143.5, 134.2,
130.6, 130.2, 129.8, 129.5, 129.5, 129.1, 128.4, 125.2, 124.1,
123.3, 120.6, 117.5, 116.0, 114.6, 110.4, 104.7, 104.2, 58.5;
MS (ESI) m/z: 474.06 (M+). Anal. calcd. for C25H19BrN2O3:
C, 63.17; H, 4.03; N, 5.89; O, 10.10% found: C, 63.20; H,
4.01; N, 5.87; O, 10.13%.
2.2.4.10. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (4-chlorophenyl) methanone (4j). Red-
dish brown semisolid. Spectroscopic analysis: IR (KBr) mmax
(cm1): 3133–2971 (Ar-CH), 1682 (C‚O), 1626 (C‚N Pyra-
zole), 1363 (C–N), 695–783 (C–Cl); 1H NMR (DMSO-d6
400 MHz) dppm: 7.68–7.39 (m, 13H, Ar-H), 4.68 (t, 1H, CH
of pyrazoline, J= 7.5 Hz), 3.69–3.99 (dd, 2H, CH2 of pyrazo-
line, J= 4.5 Hz, 6.9 Hz), 3.88 (s, 3H, OCH3);
13C NMR
(DMSO-d6 100 MHz) dppm: 165.0, 160.2, 155.5, 149.3,
143.5, 134.2, 131.0, 130.4, 129.8, 129.5, 129.3, 129.2, 128.4,
128.4, 125.3, 124.6, 123.1, 120.7, 116.5, 115.7, 114.8, 104.5,
104.3, 58.6, 38.1; MS (ESI) m/z: 430.11 (M+). Anal. calcd.
for C25H19ClN2O3: C, 69.69; H, 4.44; N, 6.50; O, 11.14%;
found: C, 69.72; H, 4.41; N, 6.53; O, 11.12%.
2.2.4.11. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (3-chlorophenyl) methanone (4k). Light
yellow solid, m.p.: 265–268 C. Spectroscopic analysis: IR
(KBr) mmax (cm
1): 3125–2968 (Ar-CH), 1678 (C‚O), 1622
(C‚N Pyrazole), 1363 (C–N), 695–784 (C–Cl); 1H NMR
(DMSO-d6 400 MHz) dppm: 7.71–7.45 (m, 13H, Ar-H), 4.88
(t, 1H, CH of pyrazoline, J= 5.8 Hz), 3.73–3.98 (dd, 2H,
CH2 of pyrazoline, J= 5.8, 6.2 Hz), 3.73 (s, 3H, OCH3);
13C
NMR (DMSO-d6 100 MHz) dppm: 165.11, 160.5, 155.8,
150.05, 144.3, 134.2, 131.6, 130.0, 129.3, 129.0, 128.5, 128.4,
125.3, 124.6, 123.2, 120.8, 116.5, 115.7, 114.8, 104.54, 104.3,
58.6, 37.6; MS (ESI) m/z: 430.11 (M+). Anal. calcd. for
C25H19ClN2O3: C, 69.69; H, 4.44; Cl, 8.23; N, 6.50; O,
11.14%; found: C, 69.73; H, 4.57; Cl, 8.24; N, 6.52; O, 11.15%.2.2.4.12. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (4-methoxyphenyl) methanone (4l).
Black semisolid. Spectroscopic analysis: IR (KBr) mmax (cm
1): 3133–2971 (Ar-CH), 1679 (C‚O), 1628 (C‚N Pyrazole),
1368 (C–N); 1H NMR (DMSO-d6 400 MHz) dppm: 7.69–7.46
(m, 13H, Ar-H), 4.68 (t, 1H, CH of pyrazoline, J= 4.6 Hz),
3.70–3.97 (dd, 2H, CH2 of pyrazoline, J= 4.6, 5.8 Hz), 3.84
(s, 6H, OCH3);
13C NMR (DMSO-d6 100 MHz) dppm:
165.1, 160.6, 155.9, 150.1, 143.1, 134.2, 131.6, 130.5, 129.4,
129.5, 128.5, 125.3, 124.6, 123.1, 120.6, 114.7, 110.3, 104.3,
59.7, 57.9, 38.0; MS (ESI) m/z: 426.16 (M+). Anal. calcd. for
C26H22N2O4: C, 73.23; H, 5.20; N, 6.57; O, 15.01%; found:
C,73.50; H, 5.23; N, 6.62; O, 15.09%.
2.2.4.13. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (2,4-dimethoxyphenyl) methanone (4m).
Yellow solid, m.p.: 232–235 C. Spectroscopic analysis: IR
(KBr) mmax (cm
1): 3128–2976 (Ar-CH), 1685 (C‚O), 1629
(C‚N Pyrazole), 1359 (C–N); 1H NMR (DMSO-d6
400 MHz) dppm: 7.64–7.51 (m, 12H, Ar-H), 4.63 (t, 1H, CH
of pyrazoline, J= 6.0 Hz), 3.74–4.01 (dd, 2H, CH2 of pyrazo-
line, J= 5.6, 8.0 Hz), 3.79 (s, 9H, OCH3);
13C NMR (DMSO-
d6 100 MHz) dppm: 165.1, 160.2, 155.4, 149.2, 143.6, 134.1,
131.1, 130.4, 129.8, 129.5, 128.4, 125.3, 124.6, 123.2, 120.7,
114.8, 110.3, 104.3, 55.7, 55.7 55.4, 37.9; MS (ESI) m/z:
456.17 (M+). Anal. calcd. for C27H24N2O5: C, 71.04; H,
5.30; N, 6.14; O, 17.52%; found: C, 71.10; H, 5.35; N, 6.12;
O, 17.75%.
2.2.4.14. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (3,4,5 trimethoxyphenyl) methanone
(4n). Brown solid, m.p.: 338–341 C. Spectroscopic analysis:
IR (KBr) mmax (cm
1): 3129–2975 (Ar-CH), 1682 (C‚O),
1625 (C‚N Pyrazole) 1371 (C–N); 1H NMR (DMSO-d6
400 MHz) dppm: 7.71–7.44 (m, 11H, Ar-H), 4.72 (t, 1H, CH
of pyrazoline, J= 7.2 Hz), 3.71–3.98 (dd, 2H, CH2 of pyrazo-
line, J= 5.0, 9.6 Hz), 3.84 (s, 12H, OCH3);
13C NMR
(DMSO-d6 100 MHz) dppm: 165.11, 160.1, 155.5, 149.3,
143.5, 134.2, 131.0, 130.4, 129.8, 129.5, 129.2, 129.1, 128.8,
128.4, 125.3, 124.7, 123.2, 120.9, 114.7, 110.3, 104.3, 55.6,
55.8 55.4, 54.1, 38.5; MS (ESI) m/z: 486.18 (M+). Anal. calcd.
for C28H26N2O6: C, 69.12; H, 5.39; N, 5.76; O, 19.73%; found:
C, 69.52; H, 4.98; N, 5.78; O, 19.75%.
2.2.4.15. 2-(3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-
dihydro-1H-pyrazole-1-carbonyl) phenylacetate (4o). Dark
brown semisolid. Spectroscopic analysis: IR (KBr) mmax (cm
1): 3130–2973 (Ar-CH), 1684 (C‚O), 1620 (C‚N Pyrazole),
1365 (C–N); 1H NMR (DMSO-d6 400 MHz) dppm: 7.70–7.44
(m, 13H, Ar-H), 4.67 (t, 1H, CH of pyrazoline, J= 5.8 Hz),
3.70–4.00 (dd, 2H, CH2 of pyrazoline, J= 5.3, 8.1 Hz), 3.79
(s, 3H, OCH3), 2.31 (s, 3H, COCH3);
13C NMR (DMSO-d6
100 MHz) dppm: 169.0, 165.9, 160.6, 155.5, 153.5, 149.3,
143.5, 134.2, 131.1, 130.4, 129.7, 129.4, 128.4, 125.3, 124.7,
123.1, 120.8, 114.8, 110.3, 104.3, 55.8, 37.9, 20.2; MS (ESI)
m/z: 454.47 (M+). Anal. calcd. for C27H22N2O5: C, 71.35; H,
4.88; N, 6.16; O, 17.60%; found: C, 71.41; H, 4.83; N, 6.12;
O, 17.55%.
2.2.4.16. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (p-tolyl) methanone (4p). Brown solid,
m.p.: 358–361 C. Spectroscopic analysis: IR (KBr) mmax (cm
Functionalized 3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole scaffolds: S26911): 3133–2971 (Ar-CH), 1679 (C‚O), 1628 (C‚N Pyrazole),
1368 (C–N); 1H NMR (DMSO-d6 400 MHz) dppm: 7.69–7.46
(m, 13H, Ar-H), 4.71 (t, 1H, CH of pyrazoline, J= 9.0 Hz),
3.78–4.02 (dd, 2H, CH2 of pyrazoline, J= 6.2, 6.8 Hz),
3.41–3.84 (s, 6H, OCH3), 2.33 (s, 3H, CH3);
13C NMR
(DMSO-d6 100 MHz) dppm: 162.1, 160.8, 155.4, 150.1,
147.5, 143.4, 135.6, 129.8, 129.5, 128.9, 128.6, 128.5, 128.5.
128.5, 127.9, 125.5, 124.7, 123.8, 121.0, 114.9, 114.8, 104.9,
64.2, 58.0, 38.0, 28.1; MS (ESI) m/z: 410.16 (M+). Anal. calcd.
for C26H22N2O3: C, 76.08; H, 5.40; N, 6.82; O, 11.69%; found:
C, 75.50; H, 5.43; N, 6.72; O, 11.15%.
2.2.4.17. (3-(Benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihy-
dro-1H-pyrazol-1-yl) (2,4-dihydroxyphenyl) methanone (4q).
Brown semisolid. Spectroscopic analysis: IR (KBr) mmax (cm
1): 1363–1317 (C–N), 3129–2976 (Ar-CH), 1668 (C‚O),
1632 (C‚N Pyrazole), 3465 (OH); 1H NMR (DMSO-d6
400 MHz) dppm: 6.65–7.43 (m, 12H, Ar-H), 5.30 (s, 2H,
OH), 4.62 (t, 1H, CH of pyrazoline, J= 8.0 Hz), 3.68–3.93
(dd, 2H, CH2 of pyrazoline, J= 5.5, 6.9 Hz), 3.38–3.77 (s,
3H, OCH3);
13C NMR (DMSO-d6 100 MHz) dppm: 167.3,
163.5, 160.7, 155.8, 149.5, 143.6, 134.2, 131.8, 130.7, 129.5,
128.3, 128.4, 125.3, 124.8, 123.1, 120.6, 115.7, 112.1, 111.0,
104.7, 58.6, 38.6; MS (ESI) m/z : 428.14 (M+). Anal. calcd.
for C25H20N2O5: C, 70.08; H, 4.71; N, 6.54; O, 18.67%; found
C, 70.12; H, 4.53; N, 6.62; O, 18.25%.
2.3. Antimicrobial activity
2.3.1. Antibacterial studies
The antibacterial activities of newly synthesized compounds
(4a-q) were determined by the well plate method in Mueller–
Hinton Agar (Arthington-Skaggs et al., 2000). The antibacte-
rial activity was carried out against 24 h old cultures of bacte-
rial strains. In this work, Escherichia coli, Staphylococcus
aureus, and Pseudomonas aeruginosa were used to investigate
the activity. The test compounds were dissolved in dimethyl
sulfoxide (DMSO) at concentration of 1 and 0.5 mg/mL.
20 mL of sterilized agar media was poured into each pre-ster-
ilized petri dish. Excess of suspension was decanted and plates
were dried by placing in an incubator at 37 C for an hour.
About 60 mL of 24 h old culture suspension was poured and
neatly swabbed with the pre-sterilized cotton swabs. Six milli-
meter diameter well was then punched carefully using a sterile
cork borer and 30 mL of test solutions of different concentra-
tions was added into each labeled well. The plates were incu-
bated for 24 h at 37 C. The inhibition zone that appeared
after 24 h, around the well in each plate was measured as zone
of inhibition in mm. Experiments were triplicates and standard
deviation was calculated.
2.3.2. Antifungal studies
Antifungal studies of newly synthesized 3-(benzofuran-2-yl)-5-
(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole scaffolds (4a-q)
were carried out againstAspergillus ﬂavus, Chrysosporium ker-
atinophilum, Candida albicans. Sabourands agar media were
prepared by dissolving peptone (10 g), D-glucose (40 g) and
agar (20 g) in distilled water (1000 mL) and adjusting the pH
to 5.7. Normal saline was used to make a suspension of spore
of fungal strains for lawning. A loopful of particular fungalstrain was transferred to 3 mL saline to get a suspension of
corresponding species (Mac Lowry et al., 1970). 20 mL of agar
media was poured into each petri dish. Excess of suspension
was decanted and plates were dried by placing in an incubator
at 37 C for 1 h. Using sterile cork borer punched carefully,
wells were made on these seeded agar plates and different con-
centrations of the test compounds in DMSO were added into
each labeled well. A control was also prepared for the plates
in the same way using solvent DMSO. The petri dishes were
prepared in triplicate and maintained at 25 C for 72 h. Anti-
fungal activity was determined by measuring the diameter of
inhibition zone. Activity of each compound was compared
with ﬂuconazole as standard and zones of inhibition were
determined for all the synthesized compounds (4a-q).2.4. Antioxidant evaluation
2.4.1. DPPH radical scavenging assay
The evaluation of antioxidant activity of newly synthesized
compounds was done by DPPH radical scavenging activity
(Blois, 1958). Internal standard BHA and the synthesized com-
pounds of different concentrations were prepared in distilled
ethanol, 1 mL of each compound solution having different
concentrations (10, 25, 50, 100, 200 and 500 lM) was taken
in different test tubes, 4 mL of 0.1 mM ethanol solution of
DPPH was added and shaken vigorously. The tubes were then
incubated in the dark room at RT for 20 min. A DPPH blank
was prepared without compound and ethanol was used for the
baseline correction. Changes (decrease) in the absorbance at
517 nm were measured using a UV–visible spectrophotometer
and the remaining DPPH was calculated. The percent decrease
in the absorbance was recorded for each concentration and
percent quenching of DPPH was calculated on the basis of
the observed decrease in absorbance of the radical. The radical
scavenging activity was expressed as the inhibition percentage
and was calculated using the formula:
Radical scavenging activity ð%Þ ¼ ½ðA0  A1Þ=A0  100
where A0 is the absorbance of the control (blank, without com-
pound) and A1 is the absorbance of the compound.
2.4.2. Inhibition of microsomal lipid peroxidation assay
Liver excised from adult male Wister rats, were homogenized
with a polytron (speed setting 7–8) in 10 mL of ice cold
Tris–HCl buffer (20 mM, pH 7.4) by the method of Liu and
Ng, 2000. The homogenate was centrifuged at 14,000 rpm
for 15 min. The supernatants (1 mL) were incubated with dif-
ferent concentrations of compounds (10, 25, 50, 100, 200 and
500 lM) in the presence of 10 lM FeSO4 and 0.1 mM ascorbic
acid at 37 C for 1 h. The reaction was terminated by the addi-
tion of 1.0 mL of trichloroacetic acid (TCA; 28%) and 1.5 mL
of thiobarbituric acid (TBA 1%). The solution was heated at
100 C for 15 min, cooled to room temperature, and centri-
fuged at 2500 rpm for 15 min, and the color of the MDA–
TBA complex in the supernatant was read at 532 nm using a
spectrophotometer. BHA was used as a positive control. The
inhibition ratio (%) was calculated using the following for-
mula: inhibition ratio ð%Þ ¼ ðA A1Þ=A 100, where A is
the absorbance of the control and A1 is the absorbance of
the test sample.
Table 1 Chemical structures and yields of synthesized compounds (4a-q).
Compound number R Yield % Compound number R Yield %
4a 87.53 4j 71.86
4b 75.26 4k 71.60
4c 68.30 4l 80.28
4d 77.00 4m 74.35
4e 65.50 4n 67.77
4f 75.06 4o 79.80
4g 82.00 4p 76.82
4h 72.80 4q 78.35
4i 69.11
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The ability of the test sample to scavenge ABTS+ radical cat-
ion was determined according to the literature method (Re
et al., 1999). The ABTS+ radical cation was pregenerated by
mixing 7 mM ABTS+ stock solution with 2.45 mM potassium
persulfate (ﬁnal concentration) and incubating for 12–16 h in
the dark at room temperature until the reaction was complete
and the absorbance was stable. The absorbance of the ABTS+
solution was equilibrated to 0.70 (±0.02) by diluting with
water at room temperature, then 1 mL was mixed with differ-
ent concentrations of the test sample (10, 25, 50, 100, 200 and
500 lM) and the absorbance was measured at 734 nm after
6 min. The scavenging capability of ABTS+ radical was calcu-
lated using the following equation:
ABTSþscavenging effect ð%Þ ¼ ½ðAc  AsÞ=Ac  100
where, Ac is the initial concentration of the ABTS
+ and As is
the absorbance of the remaining concentration of ABTS+ in
the presence of compounds.
3. Results and discussion
3.1. Chemistry
In the present work, 3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-
4,5-dihydro-1H-pyrazole scaffolds (4a-q) were obtained from
salicylaldehyde (1) as starting material (Scheme 1). Very ﬁrstly,
t-BuOK promoted synthesis of 2-acetyl benzofuran (2) was
done and it was conﬁrmed by IR, 1H NMR and mass spectral
studies. In the IR spectrum study, the appearance of acetyl car-
bonyl (C‚O) band at the region 1675 cm1 and the absence of
salicylaldehyde OH stretching at 3262–3602 cm1 and alde-
hydic (C‚O) stretching at 1720 cm1 conﬁrmed the synthesis
of 2-acetyl benzofuran (2) (Scheme 2). Whereas, in 1H NMR
spectrum, the signals resonated at d 2.25 (s, 3H, COCH3),Table 2 Inhibitory zone (diameter) mm of the synthesized compoun
Each value represents mean ± SD (n= 3).
Tested compounds concentration (mg/mL) Escherichia coli
1.0 0.5
4 2 ± 0.02 1 ± 0.0
4a 3 ± 0.02 2 ± 0.0
4b 7 ± 0.02 5 ± 0.0
4c 9 ± 0.01 8 ± 0.0
4d 2 ± 0.02 1 ± 0.0
4e 3 ± 0.01 1 ± 0.0
4f 4 ± 0.02 3 ± 0.0
4g 2 ± 0.01 1 ± 0.0
4h 19 ± 0.03 13 ± 0.0
4i 13 ± 0.01 8 ± 0.0
4j 17 ± 0.02 11 ± 0.0
4k 10 ± 0.01 5 ± 0.0
4l 4 ± 0.01 3 ± 0.0
4m 3 ± 0.02 2 ± 0.0
4n 3 ± 0.01 2 ± 0.0
4o 4 ± 0.02 3 ± 0.0
4p 5 ± 0.02 4 ± 0.0
4q 4 ± 0.01 2 ± 0.0
Streptomycin 18 ± 0.01 12 ± 0.07.38 (s, 1H, furan C–H), absence of hydroxy signal at d 5.34
(s, 1H, OH) and aldehydic signal at 10.40 (s, 1H, CHO). In
the mass spectrum, the molecular ion peak at m/z 160.05 was
noticed which conﬁrmed the formation of (2). Aldol condensa-
tion reaction between compound (2) and 4-methoxy benzalde-
hyde in the presence of LiOH H2O furnished compound (3).
The IR frequency exhibited at 1624 and 1455 cm1 due to
C‚O and C‚C functions respectively and in the 1H NMR
spectrum, signals at d 6.75 (s, 2H, CH), 3.81 (s, 3H, OCH3)
and 7.10–7.60 (m, 9H, Ar-H) conﬁrmed the condensed product
(E)-1-(benzofuran-2-yl)-3-(4-methoxyphenyl) prop-2-en-1-one
(3). The benzofuran chalcone (3) was further treated with
hydrazine hydrate to accomplish 3-(benzofuran-2-yl)-5-(4-
methoxyphenyl)-4,5-dihydro-1H-pyrazole (4), its IR spectrum
exhibited band at 3311 cm1 due to N–H function and 1H
NMR spectrum signal for N–H proton resonated at d 7.10
(s, 1H, N–H) and the absence of C–H proton at 7.66 (s, 1H,
C–H). In the ﬁnal step, 3-(benzofuran-2-yl)-5-(4-methoxy-
phenyl)-4,5-dihydro-1H-pyrazole (4) was further conjugated
with different benzoyl chlorides in the presence of triethyl-
amine to afford functionalized 3-(benzofuran-2-yl)-5-(4-
methoxyphenyl)-4,5-dihydro-1H-pyrazole scaffolds (4a-q)
(Scheme 1). The IR spectrum of all the scaffolds showed the
absence of N–H band at 3311 cm1 and presence of C‚O
stretching at the region 1664–1691 cm1. Whereas, 1H NMR
revealed the absence of N–H proton at d 7.10 (s, 1H, N–H)
which conﬁrmed the products.3.2. Antimicrobial activity
3.2.1. Antibacterial activity
The antibacterial activity of newly synthesized functionalized
3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyr-
azole scaffolds (4a-q) was determined by the well plate method.
In this study, E. coli ATCC 25922 (Gram-negative), S. aureusds (4a-q) against tested bacterial strains by the well plate method.
Staphylococcus aureus Pseudomonas aeroginosa
1.0 0.5 1.0 0.5
1 3 ± 0.01 2 ± 0.01 1 ± 0.01 1 ± 0.02
1 4 ± 0.02 3 ± 0.01 2 ± 0.01 1 ± 0.01
1 6 ± 0.02 4 ± 0.02 4 ± 0.02 3 ± 0.01
1 5 ± 0.02 5 ± 0.02 4 ± 0.02 3 ± 0.02
1 3 ± 0.01 1 ± 0.01 1 ± 0.01 1 ± 0.02
2 2 ± 0.02 1 ± 0.02 4 ± 0.02 3 ± 0.01
1 5 ± 0.01 3 ± 0.01 2 ± 0.01 1 ± 0.02
1 3 ± 0.02 2 ± 0.02 3 ± 0.01 2 ± 0.01
2 15 ± 0.01 10 ± 0.02 16 ± 0.02 13 ± 0.02
2 10 ± 0.02 8 ± 0.02 11 ± 0.02 8 ± 0.01
1 13 ± 0.01 9 ± 0.01 15 ± 0.01 12 ± 0.02
1 7 ± 0.02 4 ± 0.02 9 ± 0.01 6 ± 0.01
1 5 ± 0.01 3 ± 0.01 5 ± 0.01 4 ± 0.01
1 2 ± 0.02 1 ± 0.02 4 ± 0.02 3 ± 0.01
2 4 ± 0.01 2 ± 0.01 4 ± 0.01 3 ± 0.02
2 2 ± 0.01 1 ± 0.01 4 ± 0.01 3 ± 0.02
1 6 ± 0.02 4 ± 0.02 5 ± 0.02 3 ± 0.01
1 4 ± 0.02 2 ± 0.01 2 ± 0.02 2 ± 0.01
1 15 ± 0.02 12 ± 0.01 17 ± 0.01 13 ± 0.01
Table 3 Inhibitory zone (diameter) mm of the synthesized compounds (4a-q) against tested fungal strains by the well plate method.
Each value represents mean ± SD (n= 3).
Tested compounds concentration (mg/mL) Aspergillus ﬂavus Chrysosporium keratinophilum Candida albicans
1.0 0.5 1.0 0.5 1.0 0.5
4 2 ± 0.01 1 ± 0.01 4 ± 0.01 3 ± 0.01 4 ± 0.02 5 ± 0.01
4a 2 ± 0.02 1 ± 0.01 3 ± 0.02 2 ± 0.01 3 ± 0.01 2 ± 0.01
4b 6 ± 0.03 5 ± 0.02 4 ± 0.01 3 ± 0.02 7 ± 0.02 5 ± 0.02
4c 5 ± 0.01 4 ± 0.01 7 ± 0.02 5 ± 0.01 6 ± 0.01 4 ± 0.01
4d 2 ± 0.02 1 ± 0.01 3 ± 0.01 1 ± 0.01 4 ± 0.01 2 ± 0.02
4e 3 ± 0.01 2 ± 0.02 2 ± 0.02 1 ± 0.02 2 ± 0.02 1 ± 0.01
4f 3 ± 0.02 1 ± 0.01 4 ± 0.01 3 ± 0.01 3 ± 0.01 2 ± 0.02
4g 2 ± 0.01 1 ± 0.02 2 ± 0.02 2 ± 0.02 3 ± 0.01 3 ± 0.01
4h 9 ± 0.02 6 ± 0.01 9 ± 0.01 8 ± 0.01 11 ± 0.01 10 ± 0.02
4i 8 ± 0.01 7 ± 0.02 6 ± 0.02 6 ± 0.02 10 ± 0.02 7 ± 0.01
4j 12 ± 0.03 10 ± 0.02 17 ± 0.01 15 ± 0.02 21 ± 0.02 19 ± 0.02
4k 6 ± 0.01 5 ± 0.01 7 ± 0.02 5 ± 0.01 9 ± 0.01 8 ± 0.01
4l 5 ± 0.01 3 ± 0.01 1 ± 0.02 2 ± 0.01 4 ± 0.02 3 ± 0.01
4m 4 ± 0.02 2 ± 0.01 4 ± 0.02 3 ± 0.02 4 ± 0.02 3 ± 0.01
4n 3 ± 0.01 2 ± 0.02 4 ± 0.01 3 ± 0.01 2 ± 0.01 1 ± 0.02
4o 5 ± 0.02 4 ± 0.02 5 ± 0.01 4 ± 0.01 6 ± 0.01 4 ± 0.02
4p 4 ± 0.02 2 ± 0.01 3 ± 0.02 2 ± 0.02 3 ± 0.01 2 ± 0.02
4q 3 ± 0.01 2 ± 0.01 2 ± 0.02 3 ± 0.01 2 ± 0.02 1 ± 0.01
Fluconazole 14 ± 0.01 12 ± 0.02 17 ± 0.02 16 ± 0.01 20 ± 0.02 18 ± 0.02
Table 4 Concentration required for 50% scavenging (IC50) of
DPPH, LPO and ABTS+ radicals by the compounds (4a–q)
and the standard antioxidant BHA. Each value represents
mean ± SD (n= 3).
Tested compounds Scavenging activity (IC50)
a
DPPH LPO ABTS+
4 312 ± 0.10 142.6 ± 0.60 185.0 ± 0.12
4a >500 161.6 ± 0.21 350.85 ± 0.53
4b >500 121.6 ± 0.10 296.86 ± 0.47
4c 450 ± 0.02 97.3 ± 0.61 287.34 ± 0.12
4d 15 ± 0.63 7.12 ± 0.37 29.3 ± 0.45
4e 18 ± 0.12 12.1 ± 0.24 36.6 ± 0.61
4f 16 ± 0.65 9.7 ± 0.34 32.3 ± 0.23
4g 9 ± 0.58 4.3 ± 0.21 18.9 ± 0.11
4h 250 ± 0.52 63.3 ± 0.65 150.45 ± 0.12
4i 189 ± 0.11 28.3 ± 0.31 126.21 ± 0.54
4j 201 ± 0.23 31.2 ± 0.72 134.0 ± 0.22
4k 234 ± 0.25 38.7 ± 0.36 143.21 ± 0.24
4l 27 ± 0.66 14.6 ± 0.74 69.16 ± 0.14
4m 53 ± 0.78 18.2 ± 0.91 81.32 ± 0.27
4n 70 ± 0.23 22.3 ± 0.58 95.30 ± 0.16
4o >500 133.8 ± 0.12 309.64 ± 0.32
4p 135 ± 0.45 87.3 ± 0.71 112.16 ± 0.10
4q 10 ± 0.62 5.2 ± 0.21 19.7 ± 0.14
BHA 12.5 ± 0.12 6.4 ± 0.12 20.9 ± 0.12
a The values are expressed as lM concentration. Lower IC50
values indicate higher radical scavenging activity.
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(Gram-negative) were selected due to their infectious nature.
The test compounds were dissolved in dimethyl sulfoxide
(DMSO) at concentrations of 1 and 0.5 mg/mL. (Table 1)
The antibacterial screening revealed that some of the tested
compounds showed good inhibition against various tested
microbial strains (Table 2). The results indicated that amongthe tested compounds 4h (p-ﬂuro substituted) and 4j (p-chloro
substituted) on the 1-substituted phenyl ring showed excellent
activity against P. aeruginosa and E. coli at the concentrations
of 1 and 0.5 mg/mL compared to standard drug streptomycin.
Compounds 4i (p-bromo substituted) and 4k (m-chloro substi-
tuted) showed similar activity as that of standard, against E.
coli. Whereas, compounds 4b (p-nitro substituted) and 4c
(3,5-dinitro substituted) revealed moderately good activity
againstE. coli at 1 mg/mL concentrations. The remaining com-
pounds showed very least activity against all of the three tested
bacterial strains. From these results it could be concluded that,
the chloro, ﬂuoro, bromo, and nitro functionalized derivatives
showed better activity and the others showed less activity
against all bacterial strains.
3.2.2. Antifungal activity
Newly synthesized compounds (4a-q) were also screened for
their antifungal activity against A. ﬂavus MTCC 3306, C. ker-
atinophilumMTCC 2827 andC. albicansMTCC 3017, because
of their infectious nature. The compounds were dissolved in
DMSO and antifungal activity was determined by the well
plate method at concentrations of 1 and 0.5 mg/mL.
The antifungal result data (Table 3) indicated that, the syn-
thesized compounds showed a variable degree of inhibition
against the tested fungi. As a result, the presence of chloro sub-
stituent on the 1-substuted phenyl ring in compound (4j) has
exhibited a highly potent activity against C. albicans compared
with standard, ﬂuconazole. Compounds (4h), (4i) and (4k)
incorporating with ﬂuoro, bromo, chloro moieties on the 1-
substituted phenyl ring at different positions displayed consid-
erable activity against C. keratinophilum. The other analogues
of 3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-
pyrazole showed less activity against all the tested microorgan-
isms compared to standard. It can be concluded that some of
the prepared compounds were superior to standard against C.
Functionalized 3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole scaffolds: S2695albicans tested microbial strains. From these results it could be
generalized that, the presence of halogen substituents on the
phenyl ring showed better activity compared to other
analogues.
3.3. Antioxidant evaluation
The antioxidant potential of functionalized 3-(benzofuran-2-yl)-
5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole scaffolds (4a-q)
was determined as an index of pharmacological usefulness. Three
in vitromodel systemswere used for the evaluation of antioxidant
properties namely, 2,20-diphenyl-1-picrylhydrazyl (DPPH) radi-
cal scavenging activity (RSA), inhibition ofmicrosomal lipid per-
oxidation (LPO) assay and 2,20-azino-bis(3-ethylbenzthiazoline-
6-sulphonic acid) (ABTS+) free-radical scavenging assay. The
antioxidant properties were expressed in terms of 50% inhibitory
concentration (IC50) values (Table 4).
3.3.1. DPPH radical scavenging assay
Free radical scavenging is one of the best known mechanisms
by which antioxidants inhibit the oxidation and offer a rapid
technique for screening the radical scavenging activity of spe-
ciﬁc compounds. All tested 3-(benzofuran-2-yl)-5-(4-methoxy-
phenyl)-4,5-dihydro-1H-pyrazole scaffolds (4a-q) exhibited as
certain degree of radical scavenging activity. Initially, benzo-
furan scaffold (4) showed considerable activity, this could be
due to the presence of the electron donating methoxy group
on the phenyl ring and also the presence of the N–H func-
tional group in the pyrazole ring (Mei and Fang, 2004). Fur-
ther, introducing benzoyl chlorides having different
functional sites gave the signiﬁcant enhancement in activity.
The inhibition results of the derivatives appeared to be re-
lated to the nature of the substituent groups on the 1-susbti-
tuted phenyl ring. Compounds (4g) and (4q) exhibited better
radical scavenging potential (Table 4), this may be due to the
presence of more than one hydroxyl group on the 1-substi-
tuted phenyl ring at different positions. The conjugation of
these two benzoyl chlorides (3,4,5-tri-hydroxybenzoyl chlo-
ride and 3,5-di-hydroxybenzoyl chloride) to compound (4)
have exhibited thirty folds more activity compared to 3-(ben-
zofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole
(4) and even more higher activity than that of standard,
butylated hydroxyanisole. The presence of electron donating
substituents, such as hydroxy, methoxy and methyl on the
phenyl ring in compounds (4d-f, 4l-n and 4p) showed good
radical scavenging activity but slightly less than the standard,
whereas, compounds (4b-c and 4h-k) possessing electron
withdrawing (nitro, halogens) substituents exhibited less
activity and compound (4a) and (4o) without any substituents
and acetyl substituents showed least DPPH radical scaveng-
ing potential.
3.3.2. Inhibition of microsomal lipid peroxidation assay
A well-recognized result of oxidant injury is peroxidation of
membrane lipids to organic peroxyl radicals, which initiates
a chain reaction that may explain many membrane-mediated
effects of reactive oxygen species (ROS). The concentration-
dependent inhibitory effects of 3-(benzofuran-2-yl)-5-(4-
methoxyphenyl)-4,5-dihydro-1H-pyrazole scaffolds (4a-q) on
lipid peroxidation (LP) in liposomes were estimated by the
amount of thiobarbituric acid reactive substances (TBARS).BHA was used as a reference antioxidant (Table 4). All tested
compounds exhibited some degree of inhibitory effect on the
Fe3+/ascorbic acid-induced LP whereas, two compounds
showed higher than that of standard. Based on the IC50 values
(effective concentration at which TBARS were reduced to 50%
with respect to controls), the compounds (4g) and (4q) possess-
ing 3,4,5-tri-hydroxy and 3,5-di-hydroxy substituents on the 1-
substituted phenyl ring accounted for signiﬁcant LPO inhibi-
tors than the other 3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-
4,5-dihydro-1H-pyrazole scaffolds. The compounds (4d-f),
(4l), (4m) and (4n), have good inhibitory effect, this may be
due to the presence of hydroxyl and methoxy functions on
the 1-substituted ring respectively. Whereas, compounds hav-
ing halogens (4h-k), nitro (4b-c), acetyl (4o), methyl (4p) and
non-substituted (4a) showed lowest inhibitory effect compared
with the standard as well as other compounds.
3.3.3. ABTS radical scavenging assay
The ABTS method is based on the ability of hydrogen or
electron-donating antioxidants to decolorize the performed
radical monocation of 2,20-azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid) generated due to oxidation of ABTS with
potassium persulfate. The radical scavenging abilities showed
by 3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-
pyrazole scaffolds toward this assay typically revealed that,
compounds (4g) and (4q) exhibit signiﬁcantly better activity
than standard BHA. Whereas para, meta, ortho-free hydroxy
substituted (4d-f) and methoxy substituted (4l-n) derivatives
permit the moderate radical scavenging ability, respectively.
The presence of electron-withdrawing groups on the 1-substi-
tuted phenyl ring at 3–5 positions might not favor the activ-
ity. Thus, compounds (4b-c) and (4h-k) which contain NO2
and halogen groups on the phenyl ring at different positions
showed low ABTS radical activity than the other compounds
(Table 4). The data presented in Table 2 reﬂect that com-
pounds (4g) and (4q) exhibit effective antioxidant potential
compared to the standard BHA.
4. Conclusion
In conclusion, a novel, simple and efﬁcient methodology was
described for the synthesis of 2-acetyl benzofuran (2). Later,
we have proposed an effective strategy for the synthesis of
functionalized 3-(benzofuran-2-yl)-5-(4-methoxyphenyl)-4,5-
dihydro-1H-pyrazole scaffolds (4a-q) in good yields and evalu-
ated their antimicrobial and antioxidant activities. Antimicro-
bial studies suggest that compounds (4h) and (4j) having
halogen substituents on the pyrazole 1-substituted phenyl ring
at para position showed an excellent antibacterial and anti-
fungal activity in the well plate method. Interestingly, from
all the antioxidant assays we noted that introduction of ben-
zoyl chlorides possessing hydroxy and EDG (electron donating
group) substituents at different C-terminals to the pyrazole
ring resulted in a signiﬁcant increase in the activity. Among
all the synthesized analogues, compounds (4g) and (4q) exhibit
a signiﬁcant antioxidant potential. Whereas, compounds (4e-f)
and (4l) exhibited moderate antioxidant activity. These results
provide useful information for operating as a positive rein-
forcement of the tendency to use antimicrobial and antioxidant
properties as a guideline of the rational design of this class of
compounds.
S2696 J. Rangaswamy et al.Acknowledgements
The authors are thankful to NMR Research Center, Indian
Institute of Science, Bangalore for providing spectral data
and also thank Mr. S.K. Peethambar, Department of Studies
in Biochemistry, Kuvempu University for extending help to ac-
cess antimicrobial activity studies.
References
Abdel-Wahab, B.F., Abdel-Aziz, H.A., Ahmed, E.M., 2009. Eur. J.
Med. Chem. 44, 2632–2635.
Abdel-Wahab, B.F., Abdel-Aziz, H.A., Ahmed, E.M., 2008. Arch.
Pharm. Chem. Life Sci. 341, 734–739.
Arthington-Skaggs, B.A., Motley, M., Warnock, D.W., Morrison,
C.J., 2000. J. Clin. Microbiol. 38, 2254–2260.
Bakr, F.A., Hatem, A.A., Essam, M.A., 2009. Eur. J. Med. Chem. 44,
2632–2635.
Basawaraj, R., Goled, S., Sangapure, S.S., 2009. Indian J. Heterocycl.
Chem. 19, 201–202.
Basawaraj, R., Yadav, B., Sangapure, S.S., 2001. Indian J. Heterocycl.
Chem. 11, 31–34.
Blois, M.S., 1958. Nature 181, 1199.
Kadin, S.B., 1972. J. Med. Chem. 15, 551–552.
Kamal, M.D., Hassan, A.G., Eman, A.R., Mohey, E., Hanan, A.M.,
2006. Bioorg. Med. Chem. 14, 3672–3680.
Kao, C.L., Chern, J.W., 2001. Tetrahedron Lett. 42, 1111–1113.
Kim, S., Ahn, C., Keum, S., Koh, K., 2005. Dyes Pigm. 65, 179–182.
Kumar, H.V., Naik, N., 2010. Eur. J. Med. Chem. 45, 2–10.
Kumar, H.V., Kumar, C.K., Naik, N., 2011. Med. Chem. Res. 20,
101–108.Liu, F., Ng, T.B., 2000. Life Sci. 66, 725–735.
Mac Lowry, D.J., Jaqua, M.J., Selepak, S.T., 1970. Appl. Microbiol.
20, 46–53.
Mohamad, Y., Payal, J., 2014. Arabian J. Chem. 7, 553–596.
Mei, H.S., Fang, Y.K., 2004. Bioorg. Med. Chem. 12, 4633–4643.
Naik, N., Kumar, V.H., Harini, S.T., 2011a. Eur. J. Chem. 2, 337–341.
Naik, N., Kumar, V.H., Vidyashree, P.B., 2011b. J. Pharm. Res. 4,
2686–2689.
Parekh, S., Bhavsar, D., Savant, M., Thakrar, S., Bavishi, A., Parmar,
M., Vala, H., Radadiya, A., Pandya, N., Serly, J., Molnar, J., Shah,
A., 2011. Eur. J. Med. Chem. 46, 1942–1948.
Rangaswamy, J., Kumar, H.V., Harini, S.T., Naik, N., 2012. Bioorg.
Med. Chem. Lett. 22, 4773.
Re, R., Pellergini, N., Proteggenete, A., Pannala, A., Yang, M., Rice
Evans, C., 1999. Free Radical Biol. Med. 26, 1231–1237.
Rida, S.M., El-Hawash, S.A.M., Fahmy, H.T.Y., Hazzaa, A.A., El-
Meligy, M.M.M., 2006. Arch. Pharm. Res. 29, 826–833.
Romagnoli, R., Baraldi, P.G., Sarkar, T., Caral, C.L., Lopez, O.C.,
Carrion1, M.D., Preti1, D., Tolomeo, M., Balzarini, J., Hamel, E.,
2008. Med. Chem. 4, 558–564.
Srikant, B., Ratnesh, S., Devesh, M.S., Lalima, S., Asit, K.C., 2006. J.
Mol. Catal. A: Chem. 244, 20–24.
Ujjinamatada, R.K., Appala, R.S., Agasimundin, Y.S., 2006. J.
Heterocycl. Chem. 43, 437–441.
Vinod, U., Harun, P., Bijal, P., Sanjay, B., 2017. Arabian J. Chem. 10,
S389–S396.
Yadav, P.P., Gupta, P., Chaturvedi, A.K., Skukla, P.K., Maurya, R.,
2005. Bioorg. Med. Chem. 13, 1497–1505.
Zdemir, A.O., Zitouni, G.T., Kaplancikli, Z.A., Revial, G., Guven, K.,
2007. Eur. J. Med. Chem. 42, 403–409.
